CSF2 and non-small cell lung carcinoma: In Ni's report, patients with advanced NSCLC who had failed first-line systemic therapy were treated with IT (sintilimab 200 mg, q3w) plus SBRT (24 Gy/3 Fractions) plus GM-CSF (125 μg/m2d1-14, q3w).